Results 141 to 150 of about 207,525 (262)

Reactive Oxygen Species–Induced Modifications of Fibrin Clots as a Link Between Immune Responses and Atherothrombosis in Systemic Lupus Erythematosus

Arthritis &Rheumatology, EarlyView.
Objective Cardiovascular events are major determinants of morbidity and mortality in systemic lupus erythematosus (SLE), particularly in patients with renal involvement. Although oxidative stress has been implicated in driving vascular and renal damage in SLE, the specific mechanisms remain unclear.
Matteo Becatti, Giacomo Emmi, Alessandra Bettiol, Amanda Mannucci, Flavia Rita Argento, Eleonora Fini, Serena Borghi, Francesca Nencini, Maria Nicastro, Irene Mattioli, Elena Silvestri, Augusto Vaglio, Domenico Prisco, Claudia Fiorillo   +13 more
wiley   +1 more source

Podocyte infolding glomerulopathy in a Japanese girl with systemic lupus erythematosus. [PDF]

CEN Case Rep
Watanabe S, Imon M, Ebara M, Kensuke J, Eguchi M.   +4 more
europepmc   +1 more source

IGA NEPHROPATHY IN A PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS

, 2021
Rafaela Zarpelon Kunz, Maria Lúcia Lemos Lopes, Tatiana Freitas Tourinho, Maria Odete Esteves Hilário, Eduardo Rosa de OliveiraRaissa Velasques de Figueiredo, Thiago Willers, Rafael Coradin, Gilberto Scanagatta, Gabriela Sasso Padilha, Bruno Trevisan, Luana Ribeiro Carlos   +10 more
openalex   +1 more source

Cytokine pathways driving diverse tissue pathologies in rheumatoid arthritis

Arthritis &Rheumatology, Accepted Article.
Rheumatoid arthritis is a complex systemic disorder characterised primarily by articular inflammation and destruction with associated functional loss and reduced quality of life. RA is also associated with extra‐articular disease e.g. of the lung with potentially devastating clinical consequences.
Aurelie Najm, Lyn D. Ferguson, Iain B. McInnes   +2 more
wiley   +1 more source

Challenges in the diagnosis of systemic lupus erythematosus. [PDF]

Clin Med (Lond)
Scopes J, Md Yusof MY.
europepmc   +1 more source

A Randomized, Placebo‐Controlled Trial of Hydroxychloroquine in Incomplete Lupus

Arthritis &Rheumatology, EarlyView.
Objective Patients with features of systemic lupus erythematosus (SLE) who do not fulfill classification criteria can be designated as incomplete lupus erythematosus (ILE). This condition includes individuals with a high risk of progression to SLE. Treatment of ILE may reduce symptoms, severity, and incidence of SLE.
Nancy J. Olsen, Duanping Liao, Judith A. James, Joel M. Guthridge, Cristina Arriens, Diane Kamen, Mariko Ishimori, Daniel J. Wallace, Christopher Striebich, Sonali Narain, Benjamin F. Chong, Fan He, Eric W. Schaefer, Vernon M. Chinchilli, David R. Karp   +14 more
wiley   +1 more source

Signaling pathways in systemic lupus erythematosus and therapeutic implications. [PDF]

Front Immunol
Balogh L, Kovács VG, Nagy G, Németh T.
europepmc   +1 more source

The Impact of Some Biochemical Factors in Increasing Disease Pathogenicity of Systemic Lupus Erythematosus

, 2023
Rasha Hussain Kuba, Esraa Ahmed
openalex   +2 more sources

Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell–Targeted Therapies

Arthritis &Rheumatology, EarlyView.
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no US Food and Drug Administration (FDA)‐approved disease‐modifying therapies for SjD. In this review, we
Rachael A. Gordon, Sara S. McCoy
wiley   +1 more source

Cardiac Involvement in Systemic Lupus Erythematosus. [PDF]

Rev Cardiovasc Med
Vyas V, Vyas V, Sharma A, Kumar PA.
europepmc   +1 more source